Claus Bogh Juhl

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Kristine B. Degn, Claus Bogh Juhl, Jeppe Sturis et al. · Diabetes · 2004 · 425 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

Claus Bogh Juhl, Malene Hollingdal, Jeppe Sturis et al. · Diabetes · 2002 · 267 citations · Full text

Medicine, Endocrinology, Pharmacology +13

Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During Hypoglycemia

Kristine B. Degn, Birgitte Brock, Claus Bogh Juhl et al. · Diabetes · 2004 · 256 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Matthias von Herrath, Stephen C. Bain, Bruce W. Bode et al. · The Lancet Diabetes & Endocrinology · 2021 · 178 citations · Full text

Medicine, Endocrinology, Immunology +16